1. Scrip
  2. >>R&D

Foamix's Minocycline Foam: A Game Changer In Severe Acne?

 
• By John Davis

A topical foam formulation of the antibiotic, minocycline, is expected to be a novel entrant into the US severe acne market. After positive top-line results from a confirmatory Phase III study, Foamix is stepping-up its financing and marketing plans.

SC1809_Game Changer_649587091_1200.jpg
A topical foam formulation will be a different option for severe acne • Source: Shutterstock

Foamix Pharmaceuticals Ltd. expects to file FMX101, its topical foam formulation of minocycline, in the US by the end of 2018, for the treatment of moderate to severe acne, and is planning to set up a US sales force of up to 100 individuals, supported by a follow-on share offering on Nasdaq.

If approved, FMX101 is expected to be the only topical minocycline product for acne in the US

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’